HCW Biologics Inc.
Price Action
Technical Summary
CONSOLIDATINGHCW Biologics Inc. is in a consolidation phase, trading with mixed signals as moving averages converge. Relative strength is leading (RS Rating: 90), indicating clear outperformance against the broad market. Earnings growth of 41% provides fundamental context to the price action. Investors should exercise caution due to high volatility (170% annualized), which requires wider risk management.
Trend Template (Minervini)
Price vs Moving Averages
| Period | Value | Spread | Signal |
|---|---|---|---|
| 20 SMA | $1.70 | -35.76% | BELOW |
| 50 SMA | $1.00 | +9.20% | ABOVE |
| 100 SMA | $0.84 | +29.64% | ABOVE |
| 150 SMA | $1.13 | -3.51% | BELOW |
| 200 SMA | $1.84 | -40.85% | BELOW |
Price Performance
Technical Indicators
Risk Profile
Volume Analysis
Earnings Momentum
Growth Trends
Compounded Sales Growth
Compounded Profit Growth
Stock Price CAGR
Return on Equity
Key Metrics
Frequently Asked Questions
Is HCWB in an uptrend right now?
HCWB has a trend score of 2/4 based on Minervini's Stage Analysis. Currently showing partial alignment - 2 of 4 trend criteria are met.
Is HCWB overbought or oversold?
HCWB's RSI (14) is 44. The stock is in neutral territory, neither overbought nor oversold.
Is HCWB outperforming the market?
HCWB has a Relative Strength (RS) Rating of 90 out of 99. Yes, HCWB is a market leader, outperforming 90% of all stocks over the past 12 months.
Where is HCWB in its 52-week range?
HCWB is trading at $1.09, which is 15% of its 52-week high ($7.35) and 12% above its 52-week low ($0.25).
How volatile is HCWB?
HCWB has a Beta of 1.60 and 52-week volatility of 170%. It's more volatile than the S&P 500 - expect bigger swings.